Title:Erlotinib Hydrochloride Novel Drug Delivery Systems: A Mini Review Unravelling the Role of Micro- and Nanocarriers
Volume: 11
Issue: 4
Author(s): Chaitali Taiwade, Aditi Fulfager, Hardik Bhargave, Govind Soni and Khushwant Yadav*
Affiliation:
- Shobhaben Pratapbhai School of Pharmacy & Technology Management, SVKM’s NMIMS, Deemed to be University, Mumbai,India
Keywords:
Erlotinib, oral delivery, adverse effects, nanoparticles, liposomes, microparticles, co-delivery systems, targeting.
Abstract: Erlotinib is a tyrosine kinase inhibitor and it can treat tumors, such as pancreatic and locally
advanced lung cancer or metastatic cancer. The traditional formulation of erlotinib currently
available is an oral delivery type that presents serious side effects such as hepatotoxicity, skin rashes,
gastrointestinal disturbance, renal dysfunction, drug resistance and hematological symptoms.
Besides this, other disadvantages of erlotinib provided mostly by oral administration are the comprehensive
metabolism, low bioavailability, poor solubility and off-target impact. Overcoming
such unfavorable attributes of the medication, innovative medication delivery mechanisms like
nanocapsules, liposomes, microspheres, microparticles solid lipid nanoparticles, nanosponge, and
nanoparticles have been studied that have really shown their lead over traditional formulations.
This article summarizes the novel erlotinib drug delivery systems to boost its clinical efficacy and
reduce systemic toxicity. Novel formulations of erlotinib will offer positive outcomes in cancer
therapy and will play an important part in improving the drug's therapeutic potential.